Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Sang-Won Kim x
  • Refine by Access: All Content x
Clear All Modify Search



Galectin-3 is a cardiac biomarker for heart failure in humans. However, it has not been investigated in dogs with naturally occurring heart disease. This study aimed to compare plasma galectin-3 concentration in healthy dogs and those with myxomatous mitral valve disease (MMVD) and explore the potential association of galectin-3 with other cardiac biomarkers, inflammatory cytokines, echocardiographic estimates, and dog characteristics.


10 healthy dogs and 30 dogs with MMVD were prospectively recruited.


In this case-control study, plasma galectin-3, inflammatory cytokines, echocardiographic estimates, and other cardiac biomarkers were measured, and dog characteristics were recorded.


Plasma galectin-3 concentration was significantly higher in dogs with MMVD (2.94 [interquartile range, 1.61 to 5.20] ng/mL) than in healthy controls (1.56 [0.69 to 1.84] ng/mL, P = .009). Logistic regression analysis revealed that galectin-3 concentration and age predicted the presence of MMVD (predictive accuracy = 90.0%, P < .05). A cut-off value ≥ 1.9 ng/mL for galectin-3 differentiated healthy dogs from dogs with MMVD (70% sensitivity; 90% specificity AUC, 0.77; P = .01).


Plasma galectin-3 concentration was higher in dogs with MMVD than in healthy dogs, indicating that it is a novel cardiac biomarker in dogs with MMVD although there was no significant difference between MMVD stages.

Open access
in American Journal of Veterinary Research
in Journal of the American Veterinary Medical Association


Objective—To evaluate the intraoperative and postoperative analgesic effects of intracameral lidocaine hydrochloride injection in dogs undergoing phacoemulsification.

Animals—12 healthy Beagles with healthy eyes.

Procedures—Dogs were randomly assigned to receive 1 of 2 intracameral injections: 2% lidocaine hydrochloride solution (0.3 mL) or an equivalent amount of balanced salt solution (BSS). All dogs were treated with acepromazine (0.05 mg/kg, IV) and cefazolin (30 mg/kg, IV), and tropicamide drops were topically applied to the eyes. Anesthesia was induced with propofol and maintained with isoflurane. The initial end-tidal isoflurane concentration was maintained at 1.2%. Heart rate, respiratory rate, arterial blood pressure, esophageal temperature, inspired and end-tidal isoflurane concentrations, and oxygen saturation were recorded every 5 minutes. The allocated agent was injected intracamerally after aspiration of the same volume of aqueous humor. Ten minutes after injection, phacoemulsification was performed. After surgery began, the isoflurane concentration was adjusted according to heart rate and mean arterial blood pressure. Pain scores were recorded before surgery and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 16, and 24 hours after extubation.

Results—Isoflurane requirements were significantly higher in the BSS group than in the lidocaine group. Mean ± SD time to administration of supplementary analgesia was significantly shorter in the BSS group (1.4 ± 1.2 hours) than in the lidocaine group (4.9 ± 1.2 hours).

Conclusions and Clinical Relevance—Intracameral lidocaine injection had significant analgesic effects in dogs undergoing cataract surgery. Results of this study suggest the value of intracameral lidocaine injection as an analgesic for intraocular surgery in dogs.

Full access
in American Journal of Veterinary Research